Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Genome sequencing and assembly of Cryptosporidium serpentis

PROVIDER: PRJNA1164392 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR31263902_1.fastq.gz	Fastqsanger.gz
	SRR31263902_2.fastq.gz	Fastqsanger.gz
	SRR31263903_1.fastq.gz	Fastqsanger.gz
	SRR31263903_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 7

Similar Datasets

Cryptosporidium serpentis

Project description:Cryptosporidium serpentis whole genome shotgun sequencing and assembly

| PRJNA1234553 | ENA

Savagea serpentis strain:SN6

Project description:Savagea serpentis strain:SN6 Genome sequencing and assembly

| PRJNA673385 | ENA

Tsukamurella serpentis strain:HKU54T

Project description:Tsukamurella serpentis strain:HKU54T Genome sequencing and assembly

| PRJNA397266 | ENA

Tsukamurella serpentis strain:HKU55

Project description:Tsukamurella serpentis strain:HKU55 Genome sequencing and assembly

| PRJNA397267 | ENA

16S rRNA sequencing of cecal microbiota from neonatal mice pre- and post-weaning

Project description:Neonatal mice were susceptible to cryptosporidium infection at 1- and 2-weeks of age, but were resistant to infection at 3- and 6-weeks of age. Diet and microbial changes are known to occur during the weaning transition in mice and we hypothesized that these changes in the intestinal luminal environment might influence resistance and susceptibility to cryptosporidium infection. As one part of testing this hypothesis, cecal microbiota composition was determined by 16S ribosomal RNA sequencing of DNA isolated from the cecal contents of mice at 1 week, 2 weeks, 3 weeks, and 6 weeks of age.

2020-11-03 | E-MTAB-9100 | biostudies-arrayexpress

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

Cryptosporidium ubiquitum

Project description:Cryptosporidium ubiquitum Genome sequencing and assembly

| PRJNA246478 | ENA

Cryptosporidium cuniculus

Project description:Cryptosporidium cuniculus Genome sequencing and assembly

| PRJNA739832 | ENA

Cryptosporidium hominis

Project description:Cryptosporidium hominis Genome sequencing and assembly

| PRJNA307563 | ENA

Cryptosporidium hominis

Project description:Cryptosporidium hominis Genome sequencing and assembly